Cara discontinues AD program after oral difelikefalin fails Phase 3 KIND 1 study

Tvardi Therapeutics, Inc.

Oral difelikefalin as adjunct to TCS did not meet primary endpoint vs TCS alone in 287-patient trial.
Cara discontinues clinical program for pruritus in atopic dermatitis.
Late-stage programs for notalgia paresthetica and advanced CKD continue; data readouts expected 2H24.
Cara expects ~$100M cash at year-end 2023, including $20M milestone payment from HealthCare Royalty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.